Monitor enrollment updates and interim data from REO 033 Part A, and any announcement of Part B initiation or FDA meeting outcomes. The next catalyst would be top-line efficacy data or a regulatory submission update.
Price Chart
Executive Summary
Oncolytics Biotech presented a trial-in-progress abstract at ESMO 2026 for REO 033, a randomized Phase 2 study of pelareorep + FOLFIRI/bevacizumab in second-line RAS-mutant MSS metastatic colorectal cancer. The press release highlights FDA interactions that could support a pivotal expansion (Part B) and potential accelerated approval based on ORR, but no new clinical data, financial results, or definitive regulatory milestones were disclosed.
Key Facts
- Trial-in-progress abstract and e-poster presented at ESMO Congress 2026 for REO 033 study.
- REO 033 is a randomized, controlled, open-label Phase 2 study evaluating pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in second-line RAS-mutant, MSS mCRC.
- Primary endpoint is objective response rate (ORR); secondary endpoints include OS, PFS, DOR, and safety.
- FDA interactions have provided the opportunity to initiate a pivotal expansion (Part B) that could support accelerated approval based on ORR and full approval based on PFS.
- Prior study REO 022 showed ORR, median PFS, median OS, and median DOR more than doubled with pelareorep combination vs historical controls.
- Pelareorep has received Fast Track designation from FDA for colorectal, anal, and pancreatic cancer.
- No new clinical data, financial results, or definitive regulatory milestones were announced in this release.
Financial Impact
No financial figures disclosed. The press release references a 'multi-billion-dollar market' for second-line mCRC but provides no specific revenue, cost, or deal values.
Risk Factors
- No new clinical data presented; trial-in-progress updates are procedural and do not change the risk profile.
- REO 033 is still enrolling; delays in enrollment or unexpected safety signals could derail timelines.
- Accelerated approval pathway depends on ORR and subsequent PFS data; FDA may require additional studies.
- Oncolytics is a clinical-stage company with no approved products or recurring revenue; capital needs may require future dilutive financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3384572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $0.4986 | awaiting T+20 | — | $0.4700 (−5.74%) |
Oct 20, 2026 6d ago | Press Release | $0.4986 | awaiting T+20 | — | $0.4700 (−5.74%) |
Oct 14, 2026 12d ago | 8-K | $0.5382 | awaiting T+20 | — | $0.4700 (−12.67%) |
Oct 13, 2026 13d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.4700 (−4.08%) |
Oct 6, 2026 20d ago | DEFA14A | $0.6000 | awaiting T+20 | — | $0.4700 (−21.67%) |
Oct 6, 2026 20d ago | DEF 14A | $0.6000 | awaiting T+20 | — | $0.4700 (−21.67%) |
Sep 29, 2026 27d ago | 8-K | $0.6745 | awaiting T+20 | — | $0.4700 (−30.32%) |
Sep 28, 2026 28d ago | 8-K | $0.6630 $0.4732 | ▼ −28.63% | ▼ −28.60% | $0.4700 (−29.11%) |
Sep 10, 2026 6w ago | 8-K | $0.7720 $0.5444 | ▼ −29.48% | ▼ −31.61% | $0.4700 (−39.12%) |
Jul 20, 2026 14w ago | 8-K | $0.8500 $0.8227 | ▼ −3.21% | ▼ −7.33% | $0.4700 (−44.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers